Oh, joy! In the ever-twisting saga of Lennox Gastaut Syndrome (LGS), a condition that stubbornly resists most drugs like a toddler refusing broccoli, we’ve stumbled upon a glimmer of hope. This hope comes dressed in the fancy garb of novel treatment strategies that promise to tackle those pesky, life-quality-diminishing seizures. Because, you know, the traditional methods were just getting a tad boring.

Enter the superheroes of the story: neuromodulation and its sidekick, the minimally invasive magnetic resonance guided laser interstitial thermal therapy (MRgLITT). These two have opened the door to the cool kids of treatments – deep brain stimulation (DBS), responsive neurostimulation (RNS), and the MRgLITT corpus callosum ablation. Because why go for the simple when you can have treatments that sound like they were pulled straight from a sci-fi novel?

These cutting-edge strategies are like the new toys everyone wants, offering a beacon of hope for children battling the dragon that is drug-resistant generalized epilepsies. But, as with all shiny new toys, there are questions. Are they safe? Do they actually work? Or are they just fancy paperweights?

In this thrilling review, we’ll take you on a journey through the wonderland of these new strategies, showing you how they’re currently being used to fight the good fight. Then, we’ll put on our detective hats and critically assess whether these new kids on the block really hold a candle to the old guard – the traditional palliative epilepsy surgery approaches like vagus nerve stimulation (VNS) and open microsurgical corpus callosotomy (CC).

And because we love a good cliffhanger, we’ll wrap up with some musings on the future. What magical treatments will next emerge from the wizard’s hat? Which strategy will claim the throne as the chosen one? Stay tuned for the next episode in the saga of treating Lennox Gastaut Syndrome.